Found 105 clinical trials
A National Phase I Study of Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
- 1 views
- 22 Oct, 2022
- 1 location
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (LOC-R01)
This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine). This is a randomized Phase II trial, preceded by a dose escalation phase Ib. The objective of the phase Ib is to rule out any limiting …
- 2 views
- 28 Apr, 2022
- 12 locations
Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging
Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical
- 0 views
- 23 Apr, 2022
- 1 location
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer (ELECTRA)
This is a multi-site, global, open label study which includes a Phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with with or without brain metastases from ER positive, HER-2 negative breast cancer. Phase 1b is designed to select the recommended phase 2 dose and will …
- 0 views
- 07 Oct, 2022
- 1 location
Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND)
high-risk CNS tumors known to typically have positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME and/or Survivin) will be eligible. TAA-T will all be generated from patient peripheral
- 4 views
- 07 Oct, 2022
- 1 location
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
- 3 views
- 13 Feb, 2022
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Background More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year
- 120 views
- 24 Oct, 2022
- 11 locations
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.
- 0 views
- 12 Oct, 2022
- 1 location
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma (UCPVax-Glio)
are very frequent in central nervous system tumors, seen most commonly in gliomas25. Mutations in the TERT promoter are found in approximately 80% of primary glioblastoma (GBM). These findings
- 10 views
- 06 Jun, 2022
- 4 locations
Niraparib in Tumors Metastatic to the CNS
This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). This research study involves the study drug niraparib.
- 0 views
- 25 Mar, 2022
- 3 locations